BSE filing, BSE: 544529. Summary written from the filing by ALFA Finder's alert engine.
Aptus Pharma Ltd: key numbers
- Share price
- ₹462.70
- Market cap
- ₹793.5 Cr
- Revenue (annual)
- ₹46.57 Cr
- Net profit (annual)
- ₹4.62 Cr
- P/E (TTM)
- 171.8×Sector 46.1×
- Promoter holding
- 72.89%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aptus Pharma Ltd
All →Aptus Pharma Investor Presentation: Key Takeaways
H1 FY27 revenue ₹48.92 Cr, EBITDA ₹7.68 Cr (15.7% margin), PAT ₹5.07 Cr; revenue exceeds full FY26 (₹46.57 Cr). Trading-heavy model with rising receivables and negative operating cash flow.
Aptus Pharma H1 FY27 Results: Net Profit ₹5.1 Cr, Up 200.0% YoY
Aptus Pharma Ltd reported revenue from operations of ₹48.9 Cr (+239.6% YoY) and net profit of ₹5.1 Cr (+200.0% YoY) for H1 FY27.
- Key figure
- Net profit ₹5.1 Cr · +200.0% YoY
Aptus Pharma Other Announcement
Aptus Pharma Limited submitted the Regulation 74(5) compliance certificate for the quarter and half-year ended 30th September 2026, as received from its registrar.
Aptus Pharma Annual General Meeting
Aptus Pharma Ltd issued a corrigendum to its 16th AGM notice regarding inadvertent errors in the explanatory statement for item no. 3.
Aptus Pharma Fund Raise of ₹44.88 Cr
Aptus Pharma Limited's Board has approved raising ₹44.88 Crore through a preferential equity issue. Funds will support manufacturing capacity expansion, working capital, and Pan-India growth initiatives.
- Value
- ₹44.88 Cr
- Execution
- 36 months
Aptus Pharma Annual Report
Aptus Pharma has filed its Annual Report for FY 2025-26 with the exchange. The report includes the notice for the upcoming 16th Annual General Meeting.
Other capital structure change announcements
All →Emkay Global Financial Services Capital Structure Change
Emkay Global will invest ₹30.00 Crore in cash in wholly owned subsidiary Emkay Capital. The related-party deal completes within 90 days.
- Value
- ₹30.00 Cr
- Execution
- Within 90 days
OnEMI Technology Solutions Capital Structure Change
OnEMI will invest ₹624.15 Crore in its wholly owned subsidiary Si Creva via rights subscription. Funds come from preferential issue proceeds, completing by December 2026.
- Value
- ₹624.1 Cr
- Execution
- By end of December 2026
Meesho Capital Structure Change
Meesho approved up to Rs.400 Crore capital infusion into its wholly owned subsidiary, Meesho Payments. Board also approved a new subsidiary and further Kirana Club investments.
- Value
- ₹400.0 Cr
Womancart Capital Structure Change
Womancart Limited submitted its draft letter of offer for a rights issue of up to Rs.1,200 lakhs to eligible shareholders. The issue is pending in-principle approval from NSE Emerge, with the price, ratio and dates still blank.
- Value
- ₹12.00 Cr
Hero MotoCorp Capital Structure Change
Hero MotoCorp's board approved up to ₹300 Crore additional investment in wholly-owned subsidiary HMCL Netherlands B.V., in tranches over two years. Quarterly results were also approved.
- Value
- ₹300.0 Cr
- Execution
- 2 years, in one or more tranches
Great Eastern Shipping Company Capital Structure Change
Great Eastern Shipping bought back 88,877 equity shares on 28 October 2026 at an average of Rs.1,529.71. Total shares bought back under the open-market buyback now stand at 38,48,494.
- Value
- ₹13.60 Cr